文献速递主动脉疾病

全国性研究:感染性胸主动脉瘤的治疗

Nationwide Study on Treatment of Mycotic Thoracic Aortic Aneurysms.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2018-10-17

该全国性研究纳入2000至2016年瑞典治疗的52例感染性胸主动脉瘤患者,评估修复术后结局。胸主动脉腔内修复术(TEVAR)是最常用术式(67%),30天生存率92%、5年生存率71%;感染相关并发症发生率为17%,其中67%致命。作者认为感染相关并发症值得关注,需要随访和长期抗生素治疗。

要点

  • 52例感染性胸主动脉瘤中,TEVAR占67%,开放修补仅占4%。
  • 30天生存率92%,1年78%,5年71%。
  • 感染相关并发症9例(17%),其中6例(67%)致命,80%发生在第一年内。

核心结论

  • TEVAR常被用于治疗感染性胸主动脉瘤,与文献中的开放手术队列相比,短期和长期生存率可接受。
  • 感染相关并发症值得关注,需要随访和长期抗生素治疗。

研究设计与样本

  • 共52例患者,中位年龄71±8.1岁,男性28例(54%),破裂13例(25%),占瑞典所有胸主动脉瘤修复术的3.6%。

主要发现

  • 动脉瘤位置:主动脉弓6例(11%),降主动脉42例(81%),多部位4例(8%)。
  • 29例(56%)培养阳性,最常见病原体为金黄色葡萄球菌(16例,31%)。
  • 手术方式:TEVAR 35例(67%),开窗/分支TEVAR 8例(15%),杂交修复7例(14%),开放补片修复2例(4%)。
  • 生存率:30天92%(95%CI 88-96),3个月88%(95%CI 84-93),1年78%(73-84),5年71%(64-77)。
  • 感染相关并发症9例(17%):脓毒症3例,移植物感染3例,复发性感染性动脉瘤1例,主动脉-食管/支气管瘘2例;6例(67%)致命,80%发生在第一年内;再手术9例(17%)。

临床怎么用

  • TEVAR常被用于治疗感染性胸主动脉瘤。
  • 感染相关并发症值得关注,需要随访和长期抗生素治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mycotic aortic aneurysms are rare, life threatening, and complex. This nationwide study aimed to assess outcome after repair of mycotic thoracic aortic aneurysms (MTAAs). METHODS: Patients treated in Sweden for MTAAs between 2000 and 2016 were identified in the Swedish vascular registry (2010-16) and local patient registries (2000-09). Primary outcome was survival, and secondary outcomes included surgical strategy, rate of infection related complications (IRC), and re-operations. RESULTS: Fifty-two patients (median age 71 ± 8.1 years; 28 [54%] men, 13 [25%] ruptured) were identified (3.6% of all thoracic aortic aneurysm repairs in Sweden). Aneurysm location was aortic arch (n = 6; 11%), descending aorta (n = 42; 81%), and multiple locations (n = 4; 8%). Twenty-nine (56%) patients had positive cultures; the most prevalent agent was Staphylococcus aureus (n = 16; 31%). Operative techniques included thoracic endovascular aortic repair (TEVAR; n = 35 [67%]), fenestrated/branched TEVAR (n = 8; 15%), hybrid repair (n = 7; 14%), and open patch repair (n = 2; 4%). Survival was 92% (95% confidence interval [CI] 88-96) at 30 days, 88% (95% CI 84-93) at three months, 78% (73-84) at one year, and 71% (64-77) at five years. The mean follow up among survivors (> 90 days) was 45 months (range 4-216 months). Antibiotics were administered for a median of 15 weeks (range 0-220 weeks). IRCs occurred in nine patients (17%): sepsis (n = 3), graft infection (n = 3), recurrent mycotic aneurysm (n = 1), aorto-oesophageal/bronchial fistula (n = 2). Six (67%) IRCs were fatal; 80% occurred within the first year. Re-operations were performed in nine patients (17%). CONCLUSIONS: TEVAR was often used as treatment for MTAAs, with acceptable short- and long-term survival when compared with open cohorts in the literature. IRCs are of concern and warrant follow up and long-term antibiotic treatment.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Sörelius K, Wanhainen A, Wahlgren CM, et al. Nationwide Study on Treatment of Mycotic Thoracic Aortic Aneurysms. Eur J Vasc Endovasc Surg. 2018. PMID: 30340857. doi:10.1016/j.ejvs.2018.08.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。